CH628049A5 - Process for the preparation of ergolene derivatives - Google Patents
Process for the preparation of ergolene derivatives Download PDFInfo
- Publication number
- CH628049A5 CH628049A5 CH381477A CH381477A CH628049A5 CH 628049 A5 CH628049 A5 CH 628049A5 CH 381477 A CH381477 A CH 381477A CH 381477 A CH381477 A CH 381477A CH 628049 A5 CH628049 A5 CH 628049A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- preparation
- compounds
- derivatives
- ergolene derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
628049 628049
2 2nd
PATENTANSPRUCH Verfahren zur Herstellung von neuen Ergolenderivaten der Formel I, PATENT CLAIM Process for the production of new ergole derivatives of the formula I,
? /R1 ? / R1
CH -NH-C-IT \ CH -NH-C-IT \
2 2nd
I 10 I 10
N-CH. N-CH.
» /Rl »/ Rl
CH_-NH-C-N^ CH_-NH-C-N ^
\ \
2 2nd
N-CH. N-CH.
II II
worin Ri und R? jeweils Wasserstoff oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen bedeuten oder aber zusammen eine Alkylidenkette mit maximal 5 Kohlenstoffatomen bilden, und deren Salze mit Säuren, dadurch gekennzeichnet, dass man eine Verbindung der Formel II, where Ri and R? each represent hydrogen or an alkyl group with 1 to 4 carbon atoms or together form an alkylidene chain with a maximum of 5 carbon atoms, and their salts with acids, characterized in that a compound of the formula II,
CH2-NH-C-N^ CH2-NH-C-N ^
N-CH. N-CH.
A A
II II
H-N H-N
worin Ri und R: obige Bedeutung haben, selektiv in Stellung 2,3 reduziert und die so erhaltenen Verbindungen der Formel I gegebenenfalls in ihre Säureadditionssalze überführt. wherein R 1 and R: have the above meaning, selectively reduced to position 2,3 and the compounds of the formula I obtained in this way optionally converted into their acid addition salts.
Die Erfindung betrifft ein Verfahren zur Herstellung von neuen Ergolenderivaten der Formel I, The invention relates to a process for the preparation of new ergole derivatives of the formula I,
O R. O R.
« / 1 " / 1
CH -NH-C-N' CH -NH-C-N '
\ \
2 2nd
N-CH. N-CH.
H-N H-N
H-N. H-N.
worin Ri und R2 obige Bedeutung haben, selektiv in Stellung 2,3 reduziert und die so erhaltenen Verbindungen der Formel I gegebenenfalls in ihre Säureadditionssalze überführt. wherein R 1 and R 2 have the above meaning, selectively reduced to position 2,3 and the compounds of the formula I thus obtained are optionally converted into their acid addition salts.
Das Verfahren wird vorteilhafterweise ausgeführt, indem 20 man die Reduktion mittels eines komplexen Hydrides, wie beispielsweise Natriumborhydrid, in Gegenwart von Trifluor-essigsäure, durchgeführt. The process is advantageously carried out by carrying out the reduction using a complex hydride, such as sodium borohydride, in the presence of trifluoroacetic acid.
Die Reduktion kann beispielsweise bei Temperaturen von —10° bis +40°C erfolgen. Als Lösungsmittel verwendet man 25 Trifluoressigsäure, Äther, Tetrahydrofuran, Dioxan oder deren Gemische. Vorzugsweise setzt man einen 1,5 bis 10 molaren Überschuss an Natriumborhydrid ein. Zu Verbindungen der Formel I gelangt man aber auch durch Umsetzen von Verbindungen der Formel II mit überschüssigem Zink-30 staub in konzentrierter Salzsäure. The reduction can take place, for example, at temperatures from -10 ° to + 40 ° C. 25 trifluoroacetic acid, ether, tetrahydrofuran, dioxane or mixtures thereof are used as solvents. A 1.5 to 10 molar excess of sodium borohydride is preferably used. However, compounds of the formula I can also be obtained by reacting compounds of the formula II with excess zinc 30 dust in concentrated hydrochloric acid.
Die erfindungsgemäss hergestellten Verbindungen der Formel I sind bei Raumtemperatur kristalline Verbindungen, die mit anorganischen oder organischen Säuren beständige, bei Raumtemperatur kristallisierte Salze bilden. The compounds of the formula I prepared according to the invention are compounds which are crystalline at room temperature and which form stable salts which crystallize at room temperature with inorganic or organic acids.
3s Die neuen Verbindungen der Formel I, insbesondere 1,1 -Dimethyl-3-[6-methyl-2,3ß-dihydro-9-ergolen-8ß-ylmethyl]harnstoff, zeigen interessante pharmakologische Eigenschaften und können deshalb als Heilmittel Verwendung finden. 3s The new compounds of formula I, in particular 1,1 -dimethyl-3- [6-methyl-2,3ß-dihydro-9-ergolen-8ß-ylmethyl] urea, show interesting pharmacological properties and can therefore be used as medicines.
40 Sie zeichnen sich in der pharmakologischen Prüfung durch ausgeprägte antihypertensive Wirkung aus, wie an der wachen hypertonen Grollmannratte sowie am wachen hyper-tonen Goldblatthund mit Dosen von 0,05 bis 0,5 mg pro kg Körpergewicht des Testtieres festgestellt wurde. Ihre Anwen-45 dung bei Hypertonien jeglicher Genese ist dadurch angezeigt. 40 They are characterized in the pharmacological test by their pronounced antihypertensive effect, as was found in the awake hypertonic Grollmann rat and the awake hyper-toned gold leaf dog with doses of 0.05 to 0.5 mg per kg body weight of the test animal. Their use in hypertension of any origin is indicated.
Die zu verwendenden Dosen variieren naturgemäss je nach Art der Applikation und des zu behandelnden Zustandes. Im allgemeinen werden befriedigende Resultate erreicht mit einer täglichen Dosis von 0,01 bis 2,5 mg pro kg Körperge-50 wicht des Testtieres; diese Dosis kann nötigenfalls in 2 bis 3 Anteilen oder auch als Retardform verabreicht werden. Für grössere Säugetiere liegt die Tagesdosis bei etwa I bis 200 mg. Für orale Applikationen enthalten die Teildosen etwa 0,5 bis 100 mg der Verbindung neben festen oder flüssigen Träger-55 substanzen oder Verdünnungsmitteln. The doses to be used naturally vary depending on the type of application and the condition to be treated. In general, satisfactory results are achieved with a daily dose of 0.01 to 2.5 mg per kg of body weight of the test animal; if necessary, this dose can be administered in 2 to 3 portions or as a slow-release form. For larger mammals, the daily dose is around I to 200 mg. For oral applications, the partial doses contain about 0.5 to 100 mg of the compound in addition to solid or liquid carrier substances or diluents.
Die neuen Verbindungen der Formel I können als Arzneimittel allein oder in entsprechenden Arzneiformen für orale, enterale oder parenterale Verabreichung verwendet werden. The new compounds of the formula I can be used as pharmaceuticals alone or in appropriate pharmaceutical forms for oral, enteral or parenteral administration.
In dem nachfolgenden Beispiel, welches die Erfindung so näher erläutert, ihren Umfang aber in keiner Weise einschränken soll, erfolgen alle Temperaturangaben in Celsiusgraden. In the following example, which explains the invention in greater detail but is not intended to restrict its scope in any way, all the temperatures are given in degrees Celsius.
worin Ri und R: jeweils Wasserstoff oder eine Alkylgruppe Beispiel: where Ri and R: each hydrogen or an alkyl group Example:
mit 1 bis 4 Kohlenstoffatomen bedeuten oder aber zusammen r.s 1,1 -Dimethyl-3-[6-methyl-2,3ß-dihydro-9-ergolen-8ß- with 1 to 4 carbon atoms or together r.s 1,1 -dimethyl-3- [6-methyl-2,3ß-dihydro-9-ergolen-8ß-
eine Alkylidenkette mit maximal 5 Kohlenstoffatomen ylmethyl]harnstoff-hyxdrogenfumarat bilden, und deren Salze mit Säuren, dadurch gekennzeichnet, 10,5 g l,l-Dimethyl-3-[6-methyl-9-ergolen-8ß- form an alkylidene chain with a maximum of 5 carbon atoms ylmethyl] urea-hydrogen fumarate, and their salts with acids, characterized, 10.5 g l, l-dimethyl-3- [6-methyl-9-ergolen-8ß-
dass man eine Verbindung der Formel II, ylmethyl]harnstoff (32,4 mM) werden in 115 ml Trifluoressig- that a compound of formula II, ylmethyl] urea (32.4 mM) are in 115 ml of trifluoroacetic acid
säure gelöst. Portionenweise gibt man 1,95 g Natriumborhy-drid (5 l,5mM) zu. Nach beendeter Natriumborhydrid-Zugabe wird 20 Minuten bei Zimmertemperatur gerührt und anschliessend auf Eis/Wasser gegossen. Unter starkem Rühren gibt man festes Kaliumcarbonat zu, bis die Suspension pH 8 erreicht und schüttelt dreimal mit Methylenchlorid aus. Die vereinigten, organischen Phasen werden mit Natriumsulfat getrocknet, filtriert und eingedampft. Es resultieren 4,5 g beiger Schaum, die an 120 g Kieselgel H (Typ 60) mit Methylenchlorid/Methanol (9:1) +0,3% NH? (konz.) chro- acid dissolved. 1.95 g of sodium borohydride (5 l, 5 mM) are added in portions. After the sodium borohydride addition has ended, the mixture is stirred at room temperature for 20 minutes and then poured onto ice / water. Solid potassium carbonate is added with vigorous stirring until the suspension reaches pH 8 and shaken out three times with methylene chloride. The combined organic phases are dried with sodium sulfate, filtered and evaporated. The result is 4.5 g of beige foam, which on 120 g of silica gel H (type 60) with methylene chloride / methanol (9: 1) + 0.3% NH? (conc.) chro-
3 628049 3 628049
matographiert werden. Die resultierenden 1,6 g werden in Aceton gelöst und mit einer Lösung von 0,55 g Fumarsäure in Aceton versetzt, wobei die Titelverbindung ausfällt. be matographed. The resulting 1.6 g are dissolved in acetone and a solution of 0.55 g of fumaric acid in acetone is added, the title compound precipitating.
s Smp: ab 120° (Zers.) s MP: from 120 ° (dec.)
[aß1 = +20,9° (c = 0,44 in Äthanol/Wasser[l:l]). [aß1 = + 20.9 ° (c = 0.44 in ethanol / water [l: l]).
NMR (CDCb): 6,92 (m, 2H); 6,49 (m, 1H); 6,28 (s, 1H); 4,69 (t, 1 H, J = 6); 4,5 (m, breit, 1H); 2,90 (s, 6H); 2,55 (s, 3 H); 1,45 io (q, IH, J = 11). NMR (CDCb): 6.92 (m, 2H); 6.49 (m, 1H); 6.28 (s. 1H); 4.69 (t, 1H, J = 6); 4.5 (m, broad, 1H); 2.90 (s, 6H); 2.55 (s, 3H); 1.45 io (q, IH, J = 11).
» »
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH381477A CH628049A5 (en) | 1977-03-25 | 1977-03-25 | Process for the preparation of ergolene derivatives |
DE19782810774 DE2810774A1 (en) | 1977-03-25 | 1978-03-13 | ERGOT DERIVATIVES, THEIR USE AND PRODUCTION |
DK119778A DK147072C (en) | 1977-03-25 | 1978-03-16 | ANALOGY PROCEDURE FOR THE PREPARATION OF ERGOLEND DERIVATIVES |
SE7803040A SE7803040L (en) | 1977-03-25 | 1978-03-16 | NEW ORGANIC ASSOCIATIONS, THEIR PREPARATION AND USE |
FI780835A FI66375C (en) | 1977-03-25 | 1978-03-16 | PROCEDURE FOR FRAMSTATING AVIA THERAPEUTIC ANVAENDBARA 2,3BETA-DIHYDRO-8BETA-ERGOLENYLMETHYL-UREA-DERIVAT OCH DERAS SYRAADDITIONSSALTER |
GB11112/78A GB1596210A (en) | 1977-03-25 | 1978-03-21 | N-(2,3-dihydro-9-ergolen-8-ylmethyl) ureas |
NL7803031A NL7803031A (en) | 1977-03-25 | 1978-03-21 | ENERGY DERIVATIVES AND METHODS FOR PREPARING AND USING THESE DERIVATIVES. |
ES468133A ES468133A1 (en) | 1977-03-25 | 1978-03-22 | N-(2,3-dihydro-9-ergolen-8-ylmethyl) ureas |
IE580/78A IE46688B1 (en) | 1977-03-25 | 1978-03-23 | N-(2,3 -dihydro-9-ergolen-8 -yl methyl)ureas |
CA299,678A CA1105009A (en) | 1977-03-25 | 1978-03-23 | Ergot derivatives |
BE186239A BE865267A (en) | 1977-03-25 | 1978-03-23 | NEW DERIVATIVES OF RYE ERGOT, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
IL54342A IL54342A (en) | 1977-03-25 | 1978-03-23 | 2,3 -dihydroergolen-8 -ylmethylurea derivatives, their production and pharmaceutical compositions containing them |
IT48557/78A IT1104183B (en) | 1977-03-25 | 1978-03-23 | DERIVATIVES OF THE SIGNAL RUN THEIR PREPARATION AND THEIR APPLICATION AS MEDICATIONS (CASE 100-4781) |
AT0207078A AT366685B (en) | 1977-03-25 | 1978-03-23 | METHOD FOR PRODUCING NEW ERGOT DERIVATIVES |
PT67816A PT67816A (en) | 1977-03-25 | 1978-03-23 | PROCESS FOR THE PREPARATION OF NOVEL ORGANIC COMPOUNDS WITH PHARMACEUTICAL EFFECT |
AU34483/78A AU520738B2 (en) | 1977-03-25 | 1978-03-23 | 8-ureidomethyl ergoline derivatives |
NZ186775A NZ186775A (en) | 1977-03-25 | 1978-03-23 | 3-(6-alkyl-2,3 -dihydroergol-9-en-8 -ylmethyl)-ureas |
ZA00781714A ZA781714B (en) | 1977-03-25 | 1978-03-23 | Improvements in or relating to organic compounds |
JP3316578A JPS53119898A (en) | 1977-03-25 | 1978-03-24 | Improvement in organic compound |
SU782595601A SU1053755A3 (en) | 1977-03-25 | 1978-03-24 | Process for preparing ergoline derivatives or their salts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH381477A CH628049A5 (en) | 1977-03-25 | 1977-03-25 | Process for the preparation of ergolene derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CH628049A5 true CH628049A5 (en) | 1982-02-15 |
Family
ID=4264035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH381477A CH628049A5 (en) | 1977-03-25 | 1977-03-25 | Process for the preparation of ergolene derivatives |
Country Status (20)
Country | Link |
---|---|
JP (1) | JPS53119898A (en) |
AT (1) | AT366685B (en) |
AU (1) | AU520738B2 (en) |
BE (1) | BE865267A (en) |
CA (1) | CA1105009A (en) |
CH (1) | CH628049A5 (en) |
DE (1) | DE2810774A1 (en) |
DK (1) | DK147072C (en) |
ES (1) | ES468133A1 (en) |
FI (1) | FI66375C (en) |
GB (1) | GB1596210A (en) |
IE (1) | IE46688B1 (en) |
IL (1) | IL54342A (en) |
IT (1) | IT1104183B (en) |
NL (1) | NL7803031A (en) |
NZ (1) | NZ186775A (en) |
PT (1) | PT67816A (en) |
SE (1) | SE7803040L (en) |
SU (1) | SU1053755A3 (en) |
ZA (1) | ZA781714B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3205169A1 (en) * | 1981-02-24 | 1982-10-14 | Sandoz-Patent-GmbH, 7850 Lörrach | NEW ERGOL DERIVATIVES, THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS |
DE3411981A1 (en) * | 1984-03-28 | 1985-10-10 | Schering AG, Berlin und Bergkamen, 1000 Berlin | METHOD FOR PRODUCING 2.3-DIHYDROERGOLINES |
GB2173189B (en) * | 1985-02-21 | 1988-04-27 | Maruko Pharmaceutical Co | Ergoline derivatives and salts thereof and pharmaceutical compositions thereof |
US4798834A (en) * | 1987-08-31 | 1989-01-17 | Eli Lilly And Company | Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement |
-
1977
- 1977-03-25 CH CH381477A patent/CH628049A5/en not_active IP Right Cessation
-
1978
- 1978-03-13 DE DE19782810774 patent/DE2810774A1/en not_active Withdrawn
- 1978-03-16 DK DK119778A patent/DK147072C/en not_active IP Right Cessation
- 1978-03-16 SE SE7803040A patent/SE7803040L/en unknown
- 1978-03-16 FI FI780835A patent/FI66375C/en not_active IP Right Cessation
- 1978-03-21 NL NL7803031A patent/NL7803031A/en not_active Application Discontinuation
- 1978-03-21 GB GB11112/78A patent/GB1596210A/en not_active Expired
- 1978-03-22 ES ES468133A patent/ES468133A1/en not_active Expired
- 1978-03-23 IE IE580/78A patent/IE46688B1/en unknown
- 1978-03-23 IL IL54342A patent/IL54342A/en unknown
- 1978-03-23 AU AU34483/78A patent/AU520738B2/en not_active Expired
- 1978-03-23 BE BE186239A patent/BE865267A/en not_active IP Right Cessation
- 1978-03-23 ZA ZA00781714A patent/ZA781714B/en unknown
- 1978-03-23 CA CA299,678A patent/CA1105009A/en not_active Expired
- 1978-03-23 AT AT0207078A patent/AT366685B/en not_active IP Right Cessation
- 1978-03-23 NZ NZ186775A patent/NZ186775A/en unknown
- 1978-03-23 IT IT48557/78A patent/IT1104183B/en active
- 1978-03-23 PT PT67816A patent/PT67816A/en unknown
- 1978-03-24 JP JP3316578A patent/JPS53119898A/en active Pending
- 1978-03-24 SU SU782595601A patent/SU1053755A3/en active
Also Published As
Publication number | Publication date |
---|---|
FI66375C (en) | 1984-10-10 |
DE2810774A1 (en) | 1978-10-05 |
SE7803040L (en) | 1978-09-26 |
AT366685B (en) | 1982-04-26 |
GB1596210A (en) | 1981-08-19 |
DK147072C (en) | 1984-09-10 |
NL7803031A (en) | 1978-09-27 |
IL54342A (en) | 1981-02-27 |
DK119778A (en) | 1978-09-26 |
FI66375B (en) | 1984-06-29 |
IT7848557A0 (en) | 1978-03-23 |
DK147072B (en) | 1984-04-02 |
SU1053755A3 (en) | 1983-11-07 |
PT67816A (en) | 1978-04-01 |
JPS53119898A (en) | 1978-10-19 |
IE780580L (en) | 1978-09-25 |
CA1105009A (en) | 1981-07-14 |
ZA781714B (en) | 1979-11-28 |
ES468133A1 (en) | 1980-06-16 |
IE46688B1 (en) | 1983-08-24 |
FI780835A (en) | 1978-09-26 |
AU520738B2 (en) | 1982-02-25 |
NZ186775A (en) | 1980-12-19 |
AU3448378A (en) | 1979-09-27 |
ATA207078A (en) | 1981-09-15 |
IT1104183B (en) | 1985-10-21 |
BE865267A (en) | 1978-09-25 |
IL54342A0 (en) | 1978-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0000220B1 (en) | Dihydrouracils, process for their preparation and pharmaceuticals containing them | |
DE2938302A1 (en) | NEW DERIVATIVES OF 3- (AMINOAETHYL) - PHENOLS AND THEIR SALTS, THEIR PRODUCTION PROCESS, THEIR USE AS A MEDICINAL PRODUCT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CH645354A5 (en) | CHINOLYL GUANIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL MIXTURES CONTAINING THEM. | |
DE2461802A1 (en) | PYRAZINE DERIVATIVES | |
DE2248477A1 (en) | IMIDAZOLINE COMPOUNDS | |
CH628049A5 (en) | Process for the preparation of ergolene derivatives | |
DE2006895A1 (en) | New phenacetylguanidines and processes for their preparation | |
DE2534962C3 (en) | cis-3,4-ureylenethiophane-l, l-dioxide and process for its preparation | |
DE3336225A1 (en) | METHOD FOR PRODUCING IMIDAZOLES AND NEW INTERMEDIATE PRODUCTS FOR USE IN THIS METHOD | |
EP0007438B1 (en) | Substituted 2-phenylamino-2-imidazolines, their acid addition salts, pharmaceutical compositions containing them and process for their preparation | |
DE2106038C3 (en) | 2-Imidazolin-2-ylamino-benzo [b] thiophenes and pharmaceutical preparations containing them | |
AT390952B (en) | METHOD FOR PRODUCING NEW FURANE OR THIOPHENE DERIVATIVES | |
CH641444A5 (en) | N, N'-BIS (N-CYANO-N'-ALKYNYL) METHANIMIDAMIDYL) CYSTAMINE AND METHOD FOR THE PRODUCTION THEREOF. | |
DE3538063A1 (en) | 6-PHENETHYLAMINOALKYL-FURO- (3,4-C) -PYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THESE THERAPEUTIC COMPOSITIONS | |
DE2403416C2 (en) | 1-Phenylimidazole derivatives, their salts, processes for their preparation and their use | |
DE2142792A1 (en) | Heterocyclic compounds | |
DE3242204A1 (en) | Process for the preparation of aminoalkylfurans or -thiophenes | |
DE2740854A1 (en) | Substd. 3-indole-acetoxy-alkane sulphonic acid salts - useful as antiphlogistic and anti-hypotonic agents | |
DE1770183A1 (en) | New tertiary ester salts and processes for making the same | |
AT258915B (en) | Process for the preparation of new 4-amino-7-alkylamino-6-pteridine-N-alkyl-carboxamides | |
AT400146B (en) | Process for the preparation of 1-(2-((5-dimethylamino methyl-2-furyl)methylthio)ethyl)amino-1-methylamino-2- nitroethylene | |
DE2325328C3 (en) | Phenylethylamine derivatives, process for their preparation and agents containing them | |
DE1445415B2 (en) | Substituted imidazolidinones, their therapeutically acceptable salts and processes for their preparation | |
DE3330192A1 (en) | 4-ALKYLIMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | |
AT208355B (en) | Process for the preparation of new, substituted thiophene-3,5-disulfonamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |